新辅助化疗在晚期卵巢癌中的应用

Neoadjuvant Chemotherapy in Advanced Ovarian Cancer

目的探讨新辅助化疗在晚期卵巢癌中的应用疗效。方法方便选取该院2016年7月—2017年7月接收的74例晚期卵巢癌患者为该次研究对象,按照是否给予新辅助化疗将所有患者均分为实验组与对照组,对照组37例患者给予传统化疗,实验组37例患者给予新辅助化疗,观察两组患者预后情况。结果实验组患者平均手术时间、平均出血量、术后1个月CA125浓度分别为(146.25±21.26)min、(186.21±32.62)m L、(73.26±16.52)U/m L,各项数值均明显优于对照组:(195.21±45.26)min、(369.51±61.23)m L、(176.32±32.51)U/m L、(t=1.264、1.512、1.104,P<0.05),实验组患者疾病控制率明显优于对照组(91.8%vs 65.6%)(χ~2=5.862,P<0.05),实验组患者治疗过程中不良反应发生率明显低于对照组(5.4%vs 10.8%)(χ~2=5.023,P<0.05)。结论对于晚期卵巢癌患者给予新辅助化疗可有效提高患者近期临床治疗效果,缩短患者手术时间以及出血量,对降低患者术后并发症的发生具有重要的意义。

Objective This paper tries to observe the therapeutic effect of neoadjuvant chemotherapy in advanced ovarian cancer. Methods 74 patients with advanced ovarian cancer received in the hospital from July 2016 to July 2017 were convenient selected as the study subjects. All patients were equally divided into experimental group and control group according to whether neoadjuvant chemotherapy was given or not. The control group was given 37 patients. In the traditional chemotherapy group, 37 patients in the experimental group received neoadjuvant chemotherapy, and the prognosis of the two groups was observed. Results The average operative time, average blood loss, and CA125 concentrations at one month after surgery in the experimental group were（146.25±21.26）min,（186.21±32.62）m L,（73.26±16.52）U/m L, and the values were all excellent. In the control group,（195.21±45.26）min,（369.51±61.23）m L,（176.32±32.51）U/m L（t=1.264, 1.512, 1.104, P〈0.05）, the disease control rate of the experimental group was significantly better than that of the control group. In the control group（91.8% vs 65.6%）（χ~2=5.862, P〈0.05）, the incidence of adverse reactions in the experimental group was significantly lower than that in the control group（5.4% vs 10.8%）（χ~2=5.023, P〈0.05）. Conclusion Neoadjuvant chemotherapy for patients with advanced ovarian cancer can effectively improve the short-term clinical treatment effect, shorten the operation time and the amount of bleeding, and it is of great significance to reduce the occurrence of postoperative complications.